Schwab Charles Investment Management Inc. Has $4.36 Million Stake in Teva Pharmaceutical Industries Ltd (TEVA)

Schwab Charles Investment Management Inc. lifted its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 2.5% in the 3rd quarter, Holdings Channel reports. The firm owned 247,560 shares of the company’s stock after buying an additional 5,989 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Teva Pharmaceutical Industries were worth $4,358,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in the company. Capital Research Global Investors raised its stake in shares of Teva Pharmaceutical Industries by 13.8% during the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after purchasing an additional 9,260,426 shares during the last quarter. FMR LLC raised its stake in shares of Teva Pharmaceutical Industries by 16.7% during the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after purchasing an additional 6,115,853 shares during the last quarter. Northern Cross LLC raised its stake in shares of Teva Pharmaceutical Industries by 14.0% during the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock worth $591,169,000 after purchasing an additional 2,184,172 shares during the last quarter. Nordea Investment Management AB raised its position in Teva Pharmaceutical Industries by 2.5% in the second quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock worth $428,033,000 after acquiring an additional 311,894 shares in the last quarter. Finally, Capital World Investors raised its position in Teva Pharmaceutical Industries by 41.9% in the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock worth $367,686,000 after acquiring an additional 3,268,200 shares in the last quarter. Institutional investors and hedge funds own 51.98% of the company’s stock.

Several research analysts have issued reports on the company. Vetr cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $22.63 price objective for the company. in a research report on Thursday. ValuEngine upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Goldman Sachs Group cut Teva Pharmaceutical Industries to a “buy” rating and increased their price objective for the stock from $20.00 to $25.00 in a research report on Thursday. Mizuho upgraded Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $19.12 to $23.00 in a research report on Tuesday. Finally, Wells Fargo & Co cut Teva Pharmaceutical Industries from a “market perform” rating to an “underperform” rating and cut their price objective for the stock from $19.58 to $17.00 in a research report on Friday, January 5th. Seven analysts have rated the stock with a sell rating, sixteen have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Teva Pharmaceutical Industries presently has an average rating of “Hold” and an average target price of $21.17.

Teva Pharmaceutical Industries Ltd (TEVA) opened at $21.74 on Friday. Teva Pharmaceutical Industries Ltd has a 52-week low of $10.85 and a 52-week high of $37.94. The firm has a market capitalization of $21,500.00, a price-to-earnings ratio of -3.70, a PEG ratio of 1.36 and a beta of 0.54. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.com-unik.info/2018/01/12/schwab-charles-investment-management-inc-has-4-36-million-stake-in-teva-pharmaceutical-industries-ltd-teva.html.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit